Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-02-15
2011-12-13
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S274000, C536S027400, C544S309000, C544S311000, C544S312000, C544S314000
Reexamination Certificate
active
08076302
ABSTRACT:
A novel pyrimidine nucleoside derivative represented by the following formula (1) and a salt thereof, as well as a pharmaceutical composition comprising the same as an active ingredient have excellent antiviral properties and are useful as antiviral therapeutic agents:[wherein R represents a nitrogen-containing heterocyclic ring which may have any one of a C1-C3alkyl group or a C1-C3alkoxy group as a substituent, or a C1-C6alkyl group which has one primary amino group as a substituent].
REFERENCES:
patent: 4386076 (1983-05-01), Machida et al.
patent: 4542210 (1985-09-01), Sakata et al.
patent: 5446031 (1995-08-01), Sakata et al.
patent: 31128 (1981-07-01), None
patent: 74101 (1983-03-01), None
patent: 572669 (1993-12-01), None
patent: 56-87599 (1981-07-01), None
patent: 58-43993 (1983-03-01), None
patent: 4-505920 (1992-10-01), None
patent: WO 90/15064 (1990-12-01), None
patent: WO 92/19638 (1992-11-01), None
Razonable et al., PubMed Abstract (Herpes 10(3):60-5), Dec. 2003.
Douglas, Jr. Introduction to Viral Diseases, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 1739-1747, 1996.
Goff, PubMed Abstract (J Gene Med. 3(6):517-28) Nov.-Dec. 2001.
Bosseray et al., PubMed Abstract (Pathol. Biol. 50(8):483-92), Oct. 2002.
Kano, F. et al., 5′-O-alkyl and acyl prodrugs of 1-β-D-arabinofuranosyl-E-5-(2-bromovinyl) uracil, Antiviral Chemistry & Chemotherapy, 1994, vol. 5, No. 2, pp. 74-82.
Ashida, Noriyuki et al., Metabolism of 5′-ether prodrugs of 1-β-D-arabinofuranosyl-E-5-(2-bromovinyl) uracil in rats, Biochemical Pharmacology, 1993, vol. 46, No. 12, pp. 2201-2207.
Reefschlaeger, J. et al., Antiherpes activity of (E)-5-(2-bromovinyl)- and 5-vinyl-1-β-D-arabinofuranosyluracil and some other 5-substituted uracil arabinosyl nucleosides in two different cell lines, Antiviral Research, 1983, vol. 3, No. 3, pp. 175-187.
Machida, H. et al., In vitro anti-herpesvirus activities of 5-substituted 2′-deoxy-2′ methylidene pyrimidine nucleosides, Antiviral Chemistry & Chemotherapy, 1993, vol. 4, No. 1, pp. 11-17.
Yu, Chung-Shan et al., Synthesis of (E)-5-(2-radio-iodovinyl) arabinosyl uridine analog for probing HSV-1 thymidine kinase gene, Chemistry Letters, 2005, vol. 34, No. 10, pp. 1390-1391.
Yu, Chung-Shan et al., Syntheses of 5-fluoro and (E)-5-(2-fluorovinyl) arabinosyl uridine analogues as potential probes for the HSV-1 thymidine kinase gene, Synthesis, 2006, No. 22, pp. 3835-3840.
Kulikowski, T. et al., Pyrimidine arabinofuranosyl nucleosides with 5-substituted long, branched and unsaturated chains: synthesis and antiherpes properties, Nucleic Acids Symposium Series, 1981, vol. 9, pp. 103-106.
Machida Haruhiko
Yamamoto Masaichi
aRigen Pharmaceuticals, Inc.
Harness & Dickey & Pierce P.L.C.
Hilton Michael E.
Rao Deepak
LandOfFree
Pyrimidine nucleoside derivatives and salts thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrimidine nucleoside derivatives and salts thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimidine nucleoside derivatives and salts thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4306212